Lv4
490 积分 2023-11-03 加入
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial
1个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
1个月前
已关闭
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
1个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
1个月前
已完结
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
4个月前
已完结
A modular platform for Sterically Masked Activated Cytokines (SMACks)
4个月前
已完结
A modular platform for Sterically Masked Activated Cytokines (SMACks)
4个月前
已完结
The IL-1 family of cytokines and receptors in rheumatic diseases
4个月前
已完结
皖公网安备34019202002308
